Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H15NO2 |
Molecular Weight | 193.2423 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(C)C(=O)C1=CC=C(OC)C=C1
InChI
InChIKey=MQUIHBQDYYAEMH-UHFFFAOYSA-N
InChI=1S/C11H15NO2/c1-8(12-2)11(13)9-4-6-10(14-3)7-5-9/h4-8,12H,1-3H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26074741Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22922498 | https://www.ncbi.nlm.nih.gov/pubmed/27696217 | https://www.ncbi.nlm.nih.gov/pubmed/25438806
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26074741
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22922498 | https://www.ncbi.nlm.nih.gov/pubmed/27696217 | https://www.ncbi.nlm.nih.gov/pubmed/25438806
Methoxyphedrine (para-methoxymethcathinone, 4-methoxymethcathinone, bk-PMMA, PMMC, Methedrone, 4-MeOMC) is a phenethylamine, amphetamine, and cathinone derivative that acts as a triple reuptake/release/reversible monoamine oxidase inhibitor and used as a recreational drug. Methedrone has been found to be a potent serotonin transporter (SERT) and norepinephrine transporter (NET) inhibitor, but a weak dopamine transporter (DAT) inhibitor. Methedrone induces the transportation mediated release of NE, DA, and 5-HT from cells preloaded with monoamines making it a serotonin-norepinephrine-dopamine (SNDRA) releasing agent, also known as triple releasing agent (TRA), which is a common characteristic among drugs of abuse. The health risks associated with Methedrone are unknown but are expected to be similar to other cathinones. The deaths of two young men in southeast Sweden in 2009 were attributed to Methedrone overdose.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25438806 |
3860.0 nM [EC50] | ||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25438806 |
12.5 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26074741
Oral dose between 100 to 200 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25438806
Rat synaptosomes were used for activity evaluation. Synaptosomes were preloaded with radiolabeled substrate in Krebs-phosphate buffer for 1 h (steady state). For release assays, 9 nM [3H]1-methyl-4-phenylpyridinium ( [3H]MPP+) was used as the radiolabeled substrate for DAT, whereas 5 nM [3H]5-HT was used as a substrate for SERT. All buffers used in the release assay methods contained 1 μM reserpine to block vesicular uptake of substrates. Release assays were initiated by adding 850 μL of preloaded synaptosomes to 150 μL of test drug (Methoxyphedrine). Release was terminated by vacuum filtration, and retained radioactivity was quantified by liquid scintillation counting. Effects of test drug concentrations were expressed as percentage of maximum release, with maximum release (i.e. 100% Emax) was defined as the release produced by 10 nM tyramine for DAT and NET assay conditions, and 100 nM tyramine for SERT assay conditions.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C87053
Created by
admin on Sat Dec 16 15:55:49 GMT 2023 , Edited by admin on Sat Dec 16 15:55:49 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-4-Methoxymethcathinone
Created by
admin on Sat Dec 16 15:55:49 GMT 2023 , Edited by admin on Sat Dec 16 15:55:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
METHEDRONE
Created by
admin on Sat Dec 16 15:55:49 GMT 2023 , Edited by admin on Sat Dec 16 15:55:49 GMT 2023
|
PRIMARY | |||
|
C90631
Created by
admin on Sat Dec 16 15:55:49 GMT 2023 , Edited by admin on Sat Dec 16 15:55:49 GMT 2023
|
PRIMARY | |||
|
SUB08859MIG
Created by
admin on Sat Dec 16 15:55:49 GMT 2023 , Edited by admin on Sat Dec 16 15:55:49 GMT 2023
|
PRIMARY | |||
|
100000081456
Created by
admin on Sat Dec 16 15:55:49 GMT 2023 , Edited by admin on Sat Dec 16 15:55:49 GMT 2023
|
PRIMARY | |||
|
L7HY239I58
Created by
admin on Sat Dec 16 15:55:49 GMT 2023 , Edited by admin on Sat Dec 16 15:55:49 GMT 2023
|
PRIMARY | |||
|
530-54-1
Created by
admin on Sat Dec 16 15:55:49 GMT 2023 , Edited by admin on Sat Dec 16 15:55:49 GMT 2023
|
PRIMARY | |||
|
508
Created by
admin on Sat Dec 16 15:55:49 GMT 2023 , Edited by admin on Sat Dec 16 15:55:49 GMT 2023
|
PRIMARY | |||
|
DTXSID20862127
Created by
admin on Sat Dec 16 15:55:49 GMT 2023 , Edited by admin on Sat Dec 16 15:55:49 GMT 2023
|
PRIMARY | |||
|
216281
Created by
admin on Sat Dec 16 15:55:49 GMT 2023 , Edited by admin on Sat Dec 16 15:55:49 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106893
Created by
admin on Sat Dec 16 15:55:49 GMT 2023 , Edited by admin on Sat Dec 16 15:55:49 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)